Brainomix

🏆 We’re delighted to have been shortlisted for the UK tech awards 2026 in the AI Impact category! This recognition is especially meaningful for Brainomix, reflecting our longstanding focus on demonstrating the real-world impact of AI in healthcare. Across stroke and lung fibrosis, we’ve built a growing body of clinical evidence showing how our AI-powered imaging technology can help accelerate diagnosis, inform treatment decisions and ultimately improve care for patients. 🧠 🫁 To have that impact recognized by the prestigious UK Tech Awards, alongside some of the country’s most innovative technology companies, is a fantastic achievement for the entire Brainomix team. Congratulations to all the finalists. We look forward to the awards! 🎉 #UKTechAwards #AIwithImpact #HealthcareAI #MedTech #Brainomix #HealthTech HSBC Innovation Banking

We’re pleased to be joining forces with VOIANT® for a joint symposium at the 10th Anniversary #IPF Summit in Boston next week. Beyond FVC: Delivering Advanced Imaging Endpoints for Next-Generation IPF/ILD Trials 📅 Thursday, October 1, 2026 🕘 9:00 AM EST 📍 Boston, MA In this session, Prof. Anand Devaraj from Brainomix and Dr. Wieying Quinn Kuo, MD, PhD from #Voiant will explore: ✅ The value of quantitative #HRCT in clinical trials, from identifying meaningful differences between patients at baseline to capturing changes in lung structure that may complement conventional functional measures. ✅ What it takes to bring imaging biomarkers into trials at scale, including consistent image acquisition, robust quality assurance, centralized assessment and AI-enabled quantitative analysis. ✅ The growing evidence for imaging-based endpoints, including studies in which quantitative CT measures have been evaluated alongside #FVC to provide a more comprehensive picture of disease and treatment effects. As the role of imaging in respiratory clinical research continues to evolve, we’ll discuss how quantitative CT and AI-powered analysis can provide deeper, more objective and quantitative insights across #IPF and #ILD trials and help advance the development of new treatments. 📨 Please contact lifesciences@brainomix.com for further information, or to book a meeting with our team. We look forward to seeing colleagues in Boston. 🦞 Ross Stewart Peter George Kira Schützenhofer Hanson Wade

🔬 New research from the ENV-IPF-101 clinical trial highlights the potential of quantitative CT to provide deeper insights into treatment response in pulmonary fibrosis. 🎥 In a new HCPLive interview, Peter George discusses how quantitative CT used in the research supported the identification of change signals in patients with lung fibrosis following treatment with taladegib, alongside conventional measures of lung function. The findings highlight the potential for quantitative imaging to help us better understand disease progression and treatment response, while also supporting more targeted endpoints in future clinical trials. Watch the full interview now⤵️ https://lnkd.in/e3RSSvhq #PulmonaryFibrosis #IPF #ILD #QuantitativeCT #ClinicalTrials Endeavor BioMedicines Ross Stewart Kira Schützenhofer

"It's been a game changer in terms of the speed at which we are now accessing the imaging... and that has led to a real knock on effect on treatment times and transfer times for thrombectomy."   Dr. Jessica Rudnay at the Royal Berkshire Hospital in Reading, UK has been using Brainomix 360 Stroke since 2020. Time is brain in stroke care - faster imaging access leads to faster decisions, and faster decisions can lead to better outcomes for patients 🧠   Listen to the full video to hear how the team at Royal Berkshire NHS Foundation Trust are utilizing Brainomix ➡️ https://lnkd.in/dTwjUray

🙌 This one is for the whole Brainomix team. We’re incredibly proud to have been selected for Future Fifty, recognizing Brainomix as one of the UK’s high-growth technology companies. But milestones like this are never about one person, one team or one moment. They’re the result of the collective ambition, expertise and commitment of everyone at Brainomix. From developing our AI technology, to generating the clinical evidence, supporting our customers and ultimately helping improve outcomes for patients around the world, every person in this photo has played a part. There’s a huge amount to be proud of, and even more still to achieve. 🚀 Transforming treatment. It's what we do. 🧠🫁 #Brainomix #FutureFifty #TeamBrainomix #MedTech #AI #HealthTech Tech Nation

We’re proud to announce that Brainomix has been selected to join Future Fifty, the UK’s leading scale-up programme, alongside 24 other high-growth technology companies. It's an exciting milestone in our journey, and clear recognition of the incredible progress our team has made in scaling AI-powered medical imaging across stroke and lung disease, bringing these technologies into clinical practice around the world. We’re proud of how far we’ve come, but we’re even more excited about what comes next. 🚀 A huge thank you to our incredible team, clinical and research partners, customers and investors for helping us get here. Read the full announcement below 👇 https://lnkd.in/eEpvtAMD Learn more about the Future Fifty 2026: https://lnkd.in/d-Rdp3j #FutureFifty #ItTakesATechNation Tech Nation

Today, the National Commission into the Regulation of AI in Healthcare has published its recommendations for how the UK’s regulatory framework should evolve as AI becomes increasingly developed and adopted across healthcare. We strongly support the Commission’s vision for a regulatory framework that is Safe, Fast and Trusted - one that protects patients and manages risk, while enabling responsible innovation and timely access to technologies that can deliver meaningful benefits across the healthcare system. For those of us developing and implementing AI in healthcare, getting this balance right is critical. Strong safeguards and robust regulation should go hand in hand with an environment that enables responsible innovation and accelerates access to beneficial technologies. This is an important step towards creating a regulatory framework that can support the safe, effective and responsible adoption of AI across the NHS. #NationalAICommission #AIinHealthcare Medicines and Healthcare products Regulatory Agency Alastair Denniston Henrietta Hughes Lawrence Tallon

🌟 Two nominations. One big milestone. 🚀 We’re thrilled to be shortlisted for two European Lifestars Awards: 🏆 Medtech of the Year 🏆 Late Stage Venture Round / Series C+ Recognition for the innovation, impact and momentum behind Brainomix, and for the incredible team and partners driving us forward. Bring on the awards! 🤞 #LifestarsAwards #Medtech #DigitalHealth #AI #MedicalImaging European Lifestars Awards - Celebrating Life Science Leaders Informa

We're still riding the high from ESMINT 2026. What a great few days connecting with partners and customers from all across the globe, sharing ideas & hearing what's next for stroke care, and soaking up a sunny stretch in Marseille 🌞 A huge thank you to our partners at Medtronic Neurovascular for hosting us and for another fantastic opportunity to collaborate. Combining Medtronic's neurovascular expertise with our AI-powered imaging is exactly the kind of collaboration that helps clinicians make better-informed decisions in stroke care. P.S. to everyone who sent a postcard, we hope it reaches you safely soon. Stay tuned for another Brainomix Post in 2027 📬 ESMINT Society

NEWS: New results from a quantitative HRCT imaging analysis of our Phase 2a clinical trial for taladegib (ENV-101) in patients with idiopathic pulmonary fibrosis (#IPF) were presented at the European Respiratory Society Congress 2026. These findings contribute to a growing body of research aimed at advancing the understanding and treatment of IPF. Learn more about the results: bit.ly/4A2Hj40 #ERSCongress #ERS2026 #MedEd #MedX